Mr. Lieber joined ERX Pharmaceuticals in April 2019 as Chief Financial Officer and is a seasoned financial executive with more than 20 years of experience in financial and executive management at emerging growth life sciences companies and in investment banking. He also currently serves as a Managing Director at Danforth Advisors, a company providing integrated finance, accounting, and human resource solutions to healthcare companies. Mr. Lieber most recently served as the Chief Financial Officer of Histogenics Corporation, a publicly-held cell therapy company focused on the musculoskeletal segment of the market.
Prior to Histogenics, Mr. Lieber served as the Chief Financial Officer of Metamark Genetics, Inc., a privately held, urology-focused, molecular diagnostics company, as the Chief Financial Officer and Treasurer of Repligen Corporation, a publicly held manufacturer and supplier of high-value consumables to the life sciences industry, and the Chief Financial Officer of Xcellerex Inc. (acquired by GE Healthcare), a company engaged in the manufacture and sale of capital equipment and related consumables to the life sciences industry. Previously, Mr. Lieber served as the Chief Financial Officer of Altus Pharmaceuticals where he led all public and private capital raising activities at the company, including its $110 million initial public offering and a subsequent $90 million follow-on offering.
Prior to joining Altus, Mr. Lieber was an investment banker for 10 years where he originated and executed on numerous corporate financings and merger and acquisition transactions at SG Cowen and Salomon Brothers Inc. He received a B.S. in business administration and finance from Boston University and an M.B.A. in finance from New York University Stern School of Business.